A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
Sponsor: Cyclacel Pharmaceuticals, Inc.
Terminated
slow accrual and financial resource limitation
Other terminated trials from Cyclacel Pharmaceuticals, Inc.
- ALL, Adult · Phase PHASE1 · Oct 2023
- Leukemia · Phase PHASE2 · Feb 2019
- Cystic Fibrosis · Phase PHASE2 · Jul 2018
- Non-small Cell Lung Cancer · Phase PHASE2 · Dec 2013
- Solid Tumors · Phase PHASE1 · Nov 2009
More terminations from Cyclacel Pharmaceuticals, Inc.
A PHASE2 clinical study on Cutaneous T-cell Lymphoma (CTCL), this trial is terminated or withdrawn. The trial is conducted by Cyclacel Pharmaceuticals, Inc. and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Apr 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cyclacel Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .